---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-26-000910"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2026-07-02T11:05:55+00:00"
generated_at: "2026-07-02T11:10:07.967998+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcturus signs $80M collaboration with Thermo Fisher for ARCT-032 CF program

## Summary
- Thermo Fisher to provide up to $40M in clinical manufacturing services; Arcturus to spend up to $40M on CRO services via PPD.
- Collaboration supports Phase 3 development and potential commercialization of ARCT-032 for cystic fibrosis.
- Upon regulatory approval, Thermo Fisher receives exclusive commercial manufacturing rights for ARCT-032.
- Agreement includes technical transfer, clinical trial materials, PPQ batches, and stability studies.

## SEC filing metadata
- accession: 0001193805-26-000910
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2026-07-02T11:05:55+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380526000910/0001193805-26-000910-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380526000910/e665618_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-26-000910
- JSON: https://secwatch.observer/filing/0001193805-26-000910.json
- Plain text: https://secwatch.observer/filing/0001193805-26-000910.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.